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Abstract
Wepreviously reported the association of elevated levels of themultifunctional transcription factor, CCCTCbinding factor
(CTCF), in breast cancer cellswith the specific anti-apoptotic function of CTCF. To understand themolecularmechanisms
of this phenomenon, we investigated regulation of the human Bax gene by CTCF in breast and non–breast cells. Two
CTCF binding sites (CTSs)within theBax promoterwere identified. In all cells, breast and non-breast, active histonemodi-
fications were present at these CTSs, DNA harboring this region was unmethylated, and levels of BaxmRNA and protein
were similar. Nevertheless, up-regulation ofBaxmRNAand protein and apoptotic cell deathwere observed only in breast
cancer cells depleted of CTCF. We proposed that increased CTCF binding to the Bax promoter in breast cancer cells, by
comparison with non–breast cells, may be mechanistically linked to the specific apoptotic phenotype in CTCF-depleted
breast cancer cells. In this study, we show that CTCF binding was enriched at the Bax CTSs in breast cancer cells and
tumors; in contrast, binding of other transcription factors (SP1, WT1, EGR1, and c-Myc) was generally increased in non–
breast cells and normal breast tissues. Our findings suggest a novel mechanism for CTCF in the epigenetic regulation
of Bax in breast cancer cells, whereby elevated levels of CTCF support preferential binding of CTCF to the Bax CTSs.
In this context, CTCF functions as a transcriptional repressor counteracting influences of positive regulatory factors;
depletion of breast cancer cells from CTCF therefore results in the activation of Bax and apoptosis.
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Introduction
CCCTC binding factor (CTCF) is a multifunctional, highly conserved,
and ubiquitous 11-Zn-finger (ZF) transcription factor binding to
numerous highly diverse sequences, usually in a methylation-sensitive
manner [1,2]. A growing body of evidence supports the importance of
CTCF in the organization of nuclear space [3]. Using different genetic
and epigenetic mechanisms, CTCF regulates a wide range of genes
associated with tumor development, in particular genes involved in
growth, proliferation, differentiation, and apoptosis [1,4–7]. CTCF
functions are affected by interactions with protein partners and post-
translational modifications [8,9]; in particular, loss of CTCF poly
(ADP-ribosyl)ation is linked to breast tumorigenesis [10].
Our previous study revealed that elevated levels of CTCF in breast
cancer cell lines and tumors are associated with the resistance to apop-
tosis in breast cancer cells [11]. Using a proteomics approach, the pro-
apoptotic protein Bax was identified as a potential target for regulation
by CTCF [11]. The Bcl-2 protein family, of which Bax is a member,
plays a critical role in determining either cell death or survival [12,13].
In particular, the balance between Bax (pro-apoptotic) and Bcl-2 (anti-
apoptotic) protein levels is important for the regulation of apoptosis
[14]. Overexpression of Bax leads to apoptosis in the absence of any
stimulus, suggesting that tight regulation of Bax, from transcription
to posttranslation, is necessary for cell survival [15]. Transcriptional
control of Bax is complex, is cell context–dependent, and involves
many other transcription factors, e.g., WT1 [16], EGR1 [17], c-Myc
[18], and also p53 and p73 [19,20]; the latter two are potent regulators
of apoptosis in numerous cellular systems [21]. While the majority of
human cancers lack a functional p53 tumor suppressor protein, apop-
tosis can still occur through p53-independent apoptotic processes
[22]. Such p53-independent apoptotic pathways are very important
to identify as targets for potential therapeutic interventions.
Loss of function of Bax has been linked to tumorigenesis [23]; this
is further exemplified by the studies demonstrating improved sur-
vival of patients with Bax-expressing tumors compared with those
with no or low Bax expression (for example, [24]). Because mutations
in the Bax gene have been shown to be very rare [25], epigenetic
mechanisms are likely to be involved in differential regulation of Bax
in tumors.
In this study, we further investigate the role of CTCF in the tran-
scriptional regulation of Bax. We establish a novel function for CTCF
in the differential epigenetic regulation of Bax in breast and non–breast
cells. Our proposed model is based on higher levels of CTCF, in breast
cancer cells, that favor CTCF binding to the Bax promoter. In this
context, CTCF acts as a transcriptional repressor as depletion of CTCF
leads to activation of Bax and apoptotic cell death.
Materials and Methods
Cells and Human Breast Tissues
Breast (MCF-7, ZR75.1, T47D, and Cama1) and non–breast cell
lines (293T, HeLa, LnCap, J82, UTA6, G361, DU145, K562, and
derivatives) were maintained as described previously [11,26] and breast
cell line SUM159PT as recommended [27]. Primary human tumor
tissues together with paired peripheral tissues (referred here as “nor-
mal”) were collected during surgery from breast cancer patients treated
at Colchester General Hospital (Essex, United Kingdom), with written
consent taken before surgery. The study was approved by the Local
Ethic Committee (Reference No. MH363).
Transfection with siRNA
A panel of siRNAs, Hs_CTCF_1 siRNA through Hs_CTCF_4
and Bax siRNA (Qiagen, Manchester, United Kingdom) and CTCF
SMARTpool siRNA, non-target siRNA, and cyclophilin B siRNA [all
three from Dharmacon (Epsom, United Kingdom)], was used at
a concentration of 50 pM. Cells were seeded at a density of 2.5 ×
105 (MCF-7 and ZR75.1) or 1.2 × 105 (Cama1, 293T, and HeLa)
and transfected on the following day with siRNA and DharmaFECT2
(Dharmacon) according to the manufacturer’s protocol.
Western Blot Analysis
Lysates from cells and breast tissues were prepared as previously de-
scribed [28] and Western blot assays were conducted as reported earlier
[10,11]. Bands were visualized by the enhanced chemiluminescence
detection system (Amersham Pharmacia, Little Chalfont, United
Kingdom) according to the manufacturer’s instructions.
Primary Antibodies
A panel of different anti-CTCF antibodies with different characteris-
tics was used: rabbit polyclonal [Abcam (Cambridge, United Kingdom)
and Millipore (Billerica, MA)] , mouse monoclonal (BD Biosciences,
Oxford, United Kingdom), and the mixture of nine anti-CTCF mono-
clonal antibodies [10,29,30]. The use of these antibodies in specific
experiments is described in the figure legends. Other antibodies were
given as follows: mouse monoclonal anti–α-tubulin (Sigma-Aldrich,
St Louis, MO); RNA Polymerase II (N-20), SP1, WT1, EGR1, and
c-Myc [all rabbit polyclonal from Santa Cruz Biotechnology (Santa
Cruz, CA)];mousemonoclonalme3H3K4 andme3H3K27 (Millipore);
rabbit polyclonal PARP-1 (Enzo, Exeter, United Kingdom); mouse
monoclonal H3K9Ac and me3H3K9 (Diagenode, Liège, Belgium);
rabbit polyclonal His-Tag and Bax (Cell Signaling Technology,
Danvers, MA). The staining protocols are available on request.
CTCF and Terminal Deoxynucleotidyl Transferase–Mediated
Deoxyuridine Triphosphate Nick End Labeling Staining
For CTCF immunostaining, cells were fixed with 4% paraformal-
dehyde, permeabilized with 0.2% Triton X-100 in 1× phosphate-
buffered saline (PBS), blocked with 1% normal goat serum in 1×
PBS, and incubated with the anti-CTCF rabbit polyclonal antibody
(Abcam) and then with the fluorescein isothiocyanate (FITC)–labeled
anti-rabbit IgG (Dako, Ely, United Kingdom). To detect cells under-
going apoptosis, cells were stained by terminal deoxynucleotidyl
transferase–mediated deoxyuridine triphosphate nick end labeling
(TUNEL), using In Situ Cell Detection Kit, TMR red (Roche Applied
Science, West Sussex, United Kingdom) following the manufacturer’s
instructions. Nuclei were stained with 4,6-diamidino-2-phenylindole
dilactate (DAPI; Sigma-Aldrich) at 5 μg/ml. Images were taken using
Bio-Rad Laboratories (Hercules, CA) confocal or BX-41 (Olympus,
Southend-on-Sea, United Kingdom) microscopes. Images were analyzed
with ImageJ software [31]. The values were measured for CTCF and
TUNEL staining. The mean values for fluorescence were normal-
ized by subtracting the background values and presented as scatter plots.
Purification of RNA, Reverse Transcription, and
Real-Time Reverse Transcription–Quantitative
Polymerase Chain Reaction
Total RNA was isolated with Trisure (Bioline, London, United
Kingdom) as described by the manufacturer. RNA was treated with
TURBO DNA-free kit (Ambion, Paisley, United Kingdom); 1 μg
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of total RNA was used for reverse transcription (RT) with VERSO
cDNA kit (Thermo Fisher, Loughborough, United Kingdom). For
RT–quantitative polymerase chain reaction (qPCR), cDNA samples
were diluted at 1:10. A 25-μl PCR mix consisted of 1× SensiMix Plus
SYBR (Quantace, London, United Kingdom), 2 μl of diluted cDNA,
200 nM of each primer, and 3 mMMgCl2. Amplification, data acquisi-
tion, and analysis were carried out using the Chromo4 Real-Time PCR
(Bio-Rad Laboratories). The comparative C t method was used to assess
relative changes in mRNA levels [32]; calculations were made accord-
ing to Pfaffl [32]. Primers and conditions for RT-qPCR are described
in the Supplemental Materials and Methods section.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation (ChIP) assays were performed
from cross-linked cells (∼1 × 106) or fresh tissues (50–100 mg) using
Protein A agarose/salmon sperm DNA beads (Millipore) or Protein
A-BioVyon Gravity free flow columns (Porvair Technology, Wrexham,
United Kingdom) as described previously [33]. For experiments, tissues
were finely diced in 10 ml of Leibovitz’s L-15 media, cross-linked
with 1% of formaldehyde, and quenched for 5 minutes with glycine
(0.125 M final). The suspension was centrifuged at 1500 rpm for
3 minutes, pellet resuspended in ice-cold PBS, homogenized using
the Polytron Homogenizer, and passed through a syringe to achieve
a single cell suspension. Following centrifugation, the cell pellet was
collected and processed for ChIP as for cell lines [33]. Immuno-
precipitated DNA was extracted with phenol/chloroform and ethanol
precipitated. Real-time PCR was carried out in triplicate using 2 μl of
the immunoprecipitated DNA sample and input DNA and 300 nM
primers diluted to a final volume of 25 μl in SensiMix Plus SYBR
(Quantace). Percentage of DNA brought down by ChIP (% input)
was calculated as follows: input = AE^(Ctinput − CtChIP) × Fd ×
100% (AE is amplification efficiency, CtChIP and CtInput are thresh-
old values obtained from exponential phase of qPCR, and Fd is a dilu-
tion factor of the input DNA to balance the difference in amounts of
ChIP). Primers and conditions for qPCR are available in the Supple-
mental Materials and Methods section.
Electrophoretic mobility shift assays (EMSAs) were performed as
previously described [30,34]. In brief, eight consecutive overlapping
fragments, ∼200 bp in length, covering the Bax gene promoter from
position −600 to +550 relative to the +1 transcription start site [19]
were generated by PCR. Primers and conditions for PCR are available
on request. Fragments were then end-labeled using 32P-γ-ATP and
T4 polynucleotide kinase, incubated with the in vitro translated CTCF
(ZF domain or full length), and resolved on 5% non-denaturing
polyacrylamide gels. The correct sizes of the in vitro translated CTCF
ZF domain and the full-length CTCF protein were confirmed by
gel electrophoresis in 8% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE), in combination with Western blot
analysis (data not shown).
The Bax Gene Promoter Constructs for Luciferase
Reporter Assays
The Bax promoter region was amplified from human genomic DNA
purified from white blood cell using the following primers: (forward)
5′-ggttatctcttgggctcacaag-3′ and (reverse) 5′-tgatggacgggtccggggagca-3′.
The fragment was subcloned into the pDrive vector (Qiagen), verified
by sequencing, and then cloned into the multiple cloning sites (KpnI
and HindIII) of the promoter-less pGL2-Basic vector (Promega,
Southampton, United Kingdom).
Cell Transfection and Luciferase Assay
HeLa, 293T, and Cama1 cells (all seeded at 1.2 × 105) and MCF-7
(2.5 × 105) were transiently transfected with 5 μg of total DNA (3 μg of
reporter plasmid, 1 μg of pCi or pCiCTCF, and 1 μg of carrier DNA)
using calcium phosphate method as previously described [11]. pCiCTCF
is a vector based on pCi plasmid (Promega) expressing His-tagged human
CTCF protein [29]. Transfected cells were harvested 48 hours post-
transfection. Luciferase was measured with the Luciferase Assay System
(Promega) following themanufacturer’s instructions and calculated in rela-
tive light units after normalization against β-galactosidase activity or per-
centage of pEGFP-positive cells, used as controls for transfection efficiency.
Cell Survival Assay
Cell survival (viability) was measured using microculture tetrazolium
test (MTT) from (Sigma-Aldrich) as described in the manufacturer’s
manual. Briefly, 20 μl of 5 mg/ml MTT was added to the wells and
cells were incubated at 37°C for 3.5 hours. The medium was then
removed, and 150 μl of the MTT solution was added to the cells for
further incubation for 15 minutes at room temperature with shaking.
The OD590 and OD620 were read using Versamax plate reader. Con-
trol cells were treated with DMSO (0.1%) or water alone. Cell survival
was calculated as a percent of control (DMSO-treated in experiments
with Taxol or water-treated in experiments with Mitoxantrone) cells
as described previously [35].
Statistical Analysis
Statistical analysis was carried out using unpaired Student t test.
A significant value was detected when the probability was below the
5% confidence level (P < .05).
Results
Knockdown of CTCF with siRNA Leads to Apoptotic Cell
Death in Breast Cancer Cells
In this study, we first aimed to reproduce the anti-apoptotic effects of
CTCF in breast cancer cells using siRNA, a more efficient tool than the
previously employed antisense RNA [11]. The efficient knockdown of
CTCF (referred as CTCF-130 because it migrates as a 130-kDa protein)
was achieved by the Hs_CTCF_4 siRNA in breast cancer cells, ZR75.1,
and led to apoptosis (Figure 1A). These results were verified by immuno-
fluorescence analysis of transfected cells, whereby only TUNEL-positive
apoptotic cells contained significantly lower levels of CTCF (Figure 1C).
Similar results were obtained using another breast cancer cell line,
MCF-7 (Figure W1, A and B). No significant effects on cell viabil-
ity and apoptosis from the Hs_CTCF_4 siRNA were observed in
non–breast cancer cell lines (Figure 1, B and C , and data not shown).
Other commercially available CTCF siRNAs (Hs_CTCF_1 through
Hs_CTCF_3 siRNA and CTCF SMARTpool siRNA) were also able
to efficiently knock down CTCF and reproduce the specific apoptotic
effects observed with the Hs_CTCF_4 siRNA in breast cancer cells
(Figure W2 and data not shown). Correlation between the lower in-
tensity of CTCF staining with higher intensity of TUNEL staining
was further confirmed using unbiased quantification of the images of
breast and non–breast cells with depleted levels of CTCF (Figures 1C
and W1C ). Of note, using the same experimental conditions, the
control siRNA successfully targeted the corresponding cyclophilin B
mRNA in four cell lines following transfection with the cyclophilin B
siRNA (Figure W3). Treatment with the cyclophilin B siRNA did not
have any visible biologic effects on the cells (data not shown).
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We concluded that CTCF levels can be specifically downregulated using
different anti–CTCF siRNAs. The Hs_CTCF_4 siRNA was selected for
all subsequent experiments in this report and referred to as CTCF siRNA.
Levels of the Endogenous Bax mRNA and Protein Increase
in Breast Cancer Cells Following CTCF Knockdown
Our previous data demonstrated that the levels of Bax protein in
breast cancer cells are increased following CTCF knockdown by anti-
sense RNA [11]. To investigate whether CTCF regulates the Bax gene
at the transcriptional level, we studied Bax mRNA in representative
breast (ZR75.1 and MCF-7) and non–breast (HeLa and 293T) cells,
24 and 48 hours post-transfection with CTCF siRNA. Efficient in-
hibition of CTCF mRNA was observed in all cells at both time points,
whereas effects in cells transfected with controls, i.e., non-target siRNA
and the reagent only (“Mock”), were insignificant (Figure 2A). Following
CTCF depletion, the levels of Bax mRNA increased modestly, but sig-
nificantly, in breast cancer cells, compared with cells transfected with
non-target siRNA and “mock” transfected. In contrast, no significant
changes in Bax mRNA were detected in non–breast cells (Figure 2B).
Levels of Bax mRNA in breast cancer cells also increased following
CTCF knockdown by a different CTCF siRNA (the CTCF SMART-
pool siRNA; Figure W4A). In parallel with the mRNA, the amounts
of Bax protein also increased in breast cancer cells after CTCF de-
pletion (Figures 2C and W4B). Elevation of Bax in these cells was
Figure 1. Transient CTCF knockdown by CTCF siRNA induces specific apoptotic cell death in breast cancer cells. (A and B) Left: Levels of
CTCF are reduced in breast cancer (ZR75.1) and cervical carcinoma (HeLa) cells treated with the Hs_CTCF_4 siRNA as shown by Western
blot analysis. ZR75.1 (2.5× 105) and HeLa (1.2× 105) cells were transfectedwith 50 pM target siRNA (CTCF siRNA, “CTCFsi”) and non-target
siRNA (“NT”) or transfection reagent only (“Mock”). Forty-eight and 72 hours post-transfection, cells were collected, cellular extracts were
prepared, and equal amounts (40 μg) of total protein were loaded onto SDS-PAGE. Samples were electrophoretically separated, blotted,
and probed with the mouse monoclonal anti-CTCF antibody (BD Biosciences). The membrane was reprobed with the anti–α-tubulin anti-
body, which served as an internal control for protein loading. “CTCF-130” refers to CTCF migrating as 130-kDa protein. Right: Apoptotic cell
death is induced following CTCF knockdownwith the CTCF siRNA in ZR75.1 (A) but not in HeLa (B) cells. ZR75.1 (2.5 × 105) and HeLa (1.2 ×
105) cells were transfected with 50 pM target siRNA (CTCF siRNA, “CTCFsi”) and non-target siRNA (“NT”) or transfection reagent only
(“Mock”); apoptotic cell death was assessed by TUNEL assay. The percentage of TUNEL-positive cells was calculated 48 hours after
transfection. The results represent the mean values with the SDs (error bars) of three independent experiments. (C) Reduced CTCF levels
are associated with apoptosis in ZR75.1 cells (upper panel) but not in HeLa cells (lower panel). ZR75.1 and HeLa cells were transfected with
CTCF siRNA as above and analyzed by immunofluorescence staining with the rabbit polyclonal anti-CTCF antibody (Abcam; FITC, green
fluorescence). Apoptotic death was assessed by TUNEL staining (TMR, red fluorescence). Nuclei were visualized by DAPI. Merge, overlay
of CTCF and TUNEL staining. ZR75.1 breast cancer cells with low levels of CTCF are apoptotic (TUNEL-positive), as indicated by white
arrows, whereas HeLa cells with low levels of CTCF remain TUNEL-negative (red arrows). Cells with high levels of CTCF (not transfected
with CTCF siRNA) are TUNEL-negative (yellow arrows). Images were additionally analyzed using the ImageJ software [31]. The values were
measured for CTCF and TUNEL staining in 100 cells; the mean values for fluorescence were normalized by subtracting the background
values. The results obtained in ZR75.1 and HeLa cells are presented as scatter plots on the right.
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accompanied by the generation of the 89-kDa fragment (hallmark of
apoptosis) resulting from the cleavage of PARP-1 (116 kDa; Figure 2C)
[36,37]. The apoptotic events are likely to be mainly driven by Bax
overexpression because the levels of the cleaved 89-kDa fragment were
considerably decreased in cells with double knockdown of CTCF and
Bax (Figure 2D, left panel ). Furthermore, the assessment of cell viabil-
ity of these cells in the MTT assay revealed significantly more viable
cells in the double knockdown experiments than in those where cells
were transfected with the CTCF siRNA (Figure 2D, right panel ).
CTCF Protein Binds to Two Sites within the
Promoter-Proximal Region of Human Bax Gene
We hypothesized that CTCF may regulate transcription of the Bax
gene in breast cancer cells by interacting with its promoter. To identify
the regions bound by CTCF, we used EMSA with a series of fragments
overlapping the promoter region of Bax (Figure 3A). The DNA bind-
ing domain of CTCF (ZF) formed retarded complexes with the known
site Myc A [34] and Bax fragments 5 and 6 (Figure 3B, red arrows);
the latter was further confirmed using the full-length in vitro translated
CTCF (Figure W5). A retarded complex was also observed between the
ZF domain and fragment 7 (Figure 3B, blue arrow); however, the
DNase I footprinting analysis later revealed that the overlapping frag-
ments 6 and 7 share the common CTCF binding site, CTS-2 (see text
below and Figure 3C ). Indeed, no DNA-protein complexes were de-
tected when a shorter fragment (fragment 8), which lacks CTS-2, was
used in EMSA (Figure 3B).
In vitro DNase I footprinting assay was used to determine more pre-
cisely the locations of the CTSs within fragments 5 and 6 (Figure W6A).
Figure 2. Increased levels of Bax mRNA and protein after CTCF knockdown in breast cancer cells are associated with the hallmarks of
apoptosis. (A and B) Levels of Bax mRNA increase in breast cancer cells following CTCF knockdown. Non–breast cells HeLa (1.2 × 105)
and 293T (1.2 × 105) and breast cancer cells ZR75.1 (2.5 × 105) andMCF-7 (2.5 × 105) were transfected with 50 pMCTCF siRNA, non-target
siRNA, or transfection reagent only (“Mock”) and harvested 24 and 48 hours post-transfection. Total RNA was prepared and analyzed by
RT-qPCR. The expression levels of CTCF (2A) and BaxmRNA (2B) were calculated using the comparative C t method (ΔΔC t) and normalized
to TBP mRNA expression. Columns represent fold change of CTCF/TBP mRNA or Bax/TBP mRNA levels relative to mock-transfected cells
(designated as 1.0) as shown in the diagrams. For each sample,measurementswere done at least in triplicates; error bars represent SDs. The
difference in both CTCF and Bax mRNA levels between cells treated with CTCF siRNA and control (non-target, NT) siRNA was statistically
significant (P≤ 0.01). (C) Levels of Bax protein increase and the apoptotic markers appear in breast cancer cells following CTCF knockdown.
Non–breast and breast cancer cells were transfected as described above, collected 24 and 48 hours post-transfection, lysed, proteins sepa-
rated by SDS-PAGE, transferred onto amembrane, and analyzed byWestern blot analysis to assess the levels of CTCF, Bax, and PARP-1 (full
size, 116 kDa and the cleavage fragment, 89 kDa). Asterisks indicate the samples treated with the CTCF siRNA, and arrows indicate the
position of the PARP-1 cleavage fragment. (D) Apoptosis is considerably less pronounced in cells double transfected with CTCF siRNA
and Bax siRNA than in cells transfected with CTCF siRNA only. MCF-7 and ZR75.1 cells were transfected with 50 pM CTCF siRNA or Bax
siRNA, combination of CTCF and Bax siRNA (50 pM each), 50 pM non-target siRNA, or transfection reagent only (“Mock”) and analyzed
byWestern blot analysis as described above. The results are shown in panels on the left. Arrows indicate the position of the PARP-1 cleavage
fragment. For theMTT assay (graphs on the right), cells were prepared as described above, treated with trypsin (24 hours post-transfection),
counted, replated onto 96-well plates at 5 × 104 per well, and incubated overnight. After a total of 48 hours post-transfection, the medium
was changed to the phenol-free RPMI. Cell survival was measured usingMTT assay as described under Materials andMethods section. The
results represent themean valueswith the SDs (error bars) of three independent experiments. Abbreviations for C andD: CTCFsi, CTCF siRNA;
NT, non-target siRNA; Baxsi, Bax siRNA; M, transfection reagent only (“Mock”); C, control (extracts from untreated cells).
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Figure 2. (continued).
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Figure 3. CTCF binds to two sites within the promoter-proximal region of human Bax gene in the EMSA. (A) A schematic representation of
the approach to identify CTSs in the promoter region of the human Bax gene. The eight overlapping fragments, generated by PCR, each of
approximately 200 bp in length, are positioned within the 1150-bp promoter region of the human Bax gene. The transcription start site
identified previously [19] is indicated as +1. Fragments 5 and 6 positive for CTCF binding are depicted in red. (B) EMSA analysis of CTCF
binding to the overlapping fragments of the human Bax promoter. The DNA fragments shown in A were end-labeled with 32P, and EMSA
analyses were performed as described under Materials and Methods section. The in vitro translated 11-Zn-finger domain of CTCF (ZF) and
luciferase (control, C) were used to assess specific and non-specific binding to the DNA, respectively. F, free probe. A DNA fragment from
the human c-Myc promoter containing the CTS A (Myc A) [34] served as a positive control for CTCF binding. Specific DNA complexes with
the ZF domain of CTCF and fragments 5 and 6 are indicated by red arrows and fragment 7 by the blue arrow. (C) Nucleotide sequence of the
region of the human Bax gene promoter comprising CTSs. The previously identified transcription start site [19] is indicated (+1, blue capital
letter A). TATA box is shown in red, and the translation start site (ATG, +372) is depicted in green capital letters. Two sequences, CTS-1 and
CTS-2, protected by CTCF from DNAse I are highlighted in gray. The forward and reverse primers used to generate fragments 5 and 6 are
shown in italic. The E-box elements (potential sites for c-Myc binding) are underlined. Consensus binding sites for SP1 and WT are boxed
in blue and red, respectively. EGR1 binding sites are underlined with red lines. (D) The regions within Bax fragments 5 and 6 protected by
CTCF (named CTCF-1 and CTCF-2, respectively) contain sequences that comply with the CTCF motif identified by Kim et al. [42].
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The first CTS (CTS-1) spans the region between +117 and +185, and
the second (CTS-2) spans the region between +216 and +296, down-
stream of the transcription start site (Figure W6B). These results are
summarized schematically in Figure 3C . Notably, in both fragments,
the protected DNA sequences are long, which is a usual requirement
to form a complex with CTCF [38–40]. Moreover, each fragment con-
tains several sequences that match the CTCF “consensus”motif [41–44]
(Figure 3D). Analysis of the ChIP-seq data of CTCF binding in MCF-7
cells deposited in the UCSC genome browser revealed the enrichment
for CTCF binding in this region, thus supporting further our experi-
mental findings (Figure W6, C and D).
It was previously noted that CTSs positioned downstream of tran-
scriptional start sites, for example, in the c-MYC and hTERT genes,
are likely to act as repressors [34,45]. Our observations that CTCF
knockdown leads to up-regulation of Bax ([11] and this study),
together with two potential CTSs located downstream from the
transcription start in the promoter of the Bax gene (Figure 3C ),
suggested that CTCF negatively regulates Bax transcription. To test
this hypothesis, we generated a luciferase reporter plasmid based
on the promoter-less pGL2, driven by the 520-bp fragment of the
Bax gene promoter encompassing fragments 5 and 6 (Figure 4A)
and measured the luciferase activity following CTCF overexpres-
sion. In these experiments, CTCF overexpression led to significant
down-regulation of the reporter. The efficient production of the
ectopic His-tagged CTCF was confirmed by Western blot analysis
(Figure 4B).
The Active State of the Bax Gene in Breast and
Non–Breast Cancer Cells Is Associated with Open
Chromatin Configuration and Unmethylation of the
Bax Gene Promoter Harboring the CTSs
To investigate the molecular mechanisms of the specific anti-
apoptotic function of CTCF in breast cancer cells, we first compared
the levels of Bax mRNA and protein in a number of cell lines. Bax was
expressed in all cases, with no significant difference in Bax mRNA and
protein levels between breast and non–breast cells (Figure 5A). Bax
expression was associated with open chromatin marks (Figure 5B)
and the presence of the RNA Polymerase II at the BaxDNA fragments
containing the CTSs (Figure 5B) and the TATA box (Figure 5C ).
Figure 4. The Bax-luciferase reporter construct, containing CTSs, is negatively regulated by CTCF. (A) Cartoon illustration of the luciferase-
based reporter construct driven by the fragment of the human Bax gene promoter containing the two CTSs. Position of the transcrip-
tion start site (+1) is indicated. Both CTSs are shown as white and black boxes. (B) CTCF overexpression results in down-regulation of
the reporter. Cells were transiently transfected with the reporter construct and pCiCTCF [29] and the empty control plasmid pCi, har-
vested, and assayed for luciferase activity as described in Materials and Methods section. Bars represent fold changes of lucifer-
ase activity in the cells transfected with the plasmid expressing CTCF (pCiCTCF) [29] compared with the controls, mock-transfected
or transfected with the empty vector pCi, respectively (taken as 1); the numerical values are shown under each column. The mean of
three independent experiments is shown. Error bars indicate SDs. The difference in luciferase values between cells transfected with
pCiCTCF and the corresponding control (pCi) were statistically significant (P < .05). The levels of the exogenous, His-tagged CTCF were
assessed by Western blot assay using the anti–His-Tag antibody, respectively; these results are shown below the graphs. The membrane
was reprobed with an anti-tubulin antibody (loading control). “CTCF” refers to the exogenous CTCF produced from pCiCTCF; pCi is an
empty vector.
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These findings are further supported by the data from the UCSC
genome browser showing the presence of marks associated with active
transcription, in the CTSs within the Bax promoter, in a variety of
breast and non–breast cancer cells (Figure W7).
We next tested if the differential binding of CTCF to the Bax pro-
moter was methylation dependent using the bisulfite sequencing strat-
egy. We found that the CTCF binding regions of the Bax promoter
were unmethylated in all the cell lines (breast and non-breast) and
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breast tissues (normal and tumor) analyzed (Figure W8). Therefore,
different epigenetic mechanism(s) may be in operation to provide
differential regulation of Bax in breast and non–breast cells.
The CTSs Are Enriched with CTCF in Breast Cancer Cells
Compared with Normal Breast and Non–Breast Cancer Cells
We proposed that the specific apoptotic phenotype in CTCF-
depleted breast cancer cells may be explained by the increased CTCF
binding to the Bax promoter in breast compared with the non–breast
cells. To explore this possibility, we investigated the in vivo occupancy
by CTCF of fragments 5 and 6, harboring CTS-1 and CTS-2, respec-
tively, in breast and non–breast cell lines using ChIP assay [30,42].
As shown in Figure 6A, considerable enrichment of CTCF binding
to both fragments was observed in the two breast cancer cell lines
inspected. In contrast, in non–breast cell lines, CTCF binding to
either of these fragments was reduced.
We then asked whether the CTSs in non–breast cells may be
enriched with other transcription factors than CTCF. Bioinformatics
(MatInspector, www.genomatrix.de) and literature analyses were used
to identify transcription factors that could potentially bind to the Bax
promoter region containing CTSs. Four such factors were selected on
the basis of the published data and high score matches: WT1 [16],
EGR1 [17], c-Myc [18], and SP1 (their positions are indicated in
Figure 3C ). ChIP experiments revealed no significant differences in
the enrichment of fragment 5 (CTS-1) by SP1, WT1, and EGR1,
whereas the enrichment by c-Myc was higher in non–breast cells (Fig-
ure 6B, left). In contrast, the occupancy of fragment 6 (CTS-2) by all
factors was significantly lower in breast cells than in non–breast cells
(Figure 6B, right). These observations suggest differential functions
of the two CTSs. This line of investigation was not pursued in this
study because of close proximity of the CTSs; further evidence will
be required to corroborate this finding.
We then investigated the link between Bax mRNA expression and
the CTS occupancy by CTCF and other factors in breast tumors and
paired peripheral (referred here as “normal”) tissues. Consistent with
published data [46], Bax mRNA was found to be expressed at higher
levels in normal tissues compared with the corresponding paired tumors
and this was also observed with the levels of Bax protein (Figure 5A).
Moreover, enrichment of CTCF binding to both Bax fragments 5 and
6 was detected in tumor tissues, compared with normal breast tissues
(Figures 6C and W9, and data not shown). To study the occupancy
of these fragments by other factors, the paired tissue specimens 1094,
which provided sufficient material to perform multiple ChIP assays,
were used. As shown in Figure 6C , similar to CTCF, WT1 was
enriched in the tumor tissue, whereas binding of SP1, EGR1, and
c-Myc was higher in the normal tissue.
We then asked whether the levels of the Bax protein and the bind-
ing of CTCF to the CTSs would be the same or different in a non–
breast cell line stably overexpressing ectopic CTCF. For this purpose,
we used leukemia cells K562-G1 previously generated and character-
ized in our laboratory [26]. As shown in Figure 7A, K562-G1 cells
produce considerably more CTCF protein than control cells (original
K562 unmodified cell line and K562EV stably transfected with the
backbone empty plasmid pcDNA3), whereas no change in Bax levels
can be observed. There was no difference in CTCF binding to frag-
ments 5 and 6, and the occupancies of these fragments by WT1, SP1,
EGR1, and c-Myc were also generally similar in the three cell lines
(Figure 7B). Reduction of CTCF levels in the original K562 and
K562-G1 cells led to increased proliferation and inhibition of erythroid
differentiation but had no effect on apoptotic cell death ([26] and data
not shown).
From these results, we conclude that in breast cancer cells (tissues
and cell lines) CTCF binding to the Bax promoter proximal regions is
increased, compared with non–breast cells and normal breast tissues
where other transcription factors are predominantly bound.
Discussion
In this report, we present experimental evidence for the transcriptional
regulation of the pro-apoptotic gene Bax by CTCF in breast cancer
cells. Using specific CTCF siRNA, we confirmed our previous obser-
vations that knockdown of CTCF leads to apoptosis specifically in
breast cancer cells but not in non–breast cancer cells. This study clari-
fied the link between CTCF and Bax, whereby depletion of CTCF
led to the increase in levels of Bax mRNA and protein in breast cancer
cells but not in non–breast cancer cells. Although the changes in Bax
mRNA expression were modest, they were sufficient to induce apop-
tosis; similar observations were described in another report [47]. It
Figure 5. The active state of the Bax gene in different cell lines and tissues is associated with open chromatin hallmarks. (A) Analysis of Bax
mRNA and protein levels in breast and non–breast cell lines and in normal and tumor breast tissues. Total RNAswere prepared and analyzed
by RT-qPCR as described under Materials and Methods section. The expression levels of BaxmRNAwere calculated using the comparative
C t method (ΔΔC t) and normalized to TBP mRNA expression. For each sample, measurements were done at least in triplicates. The com-
parison between the mean Bax mRNA levels in normal and tumor tissues (n = 5) is shown in the inserted diagram. Error bars represent
SDs. Western blot analyses of different cell lines (left) and selected tissue samples (right) are represented by the images inserted above
bars. Cellular or tissue extracts (20 μg of total protein) were loaded onto SDS-PAGE, separated, blotted, and probed with the anti-Bax
antibody. The same membrane was stripped and reprobed with the α-tubulin antibody (loading control). For cell samples, the developed
films were scanned using the ImageJ software and images were quantified. The ratios of the intensity of the Bax bands over the intensity of
the corresponding α-tubulin bands were determined and expressed as fold change relative to the lowest Bax/α-tubulin ratio (designated
as 1.0). Numbers below each lane represent these results. (B) Open chromatin marks and RNA Polymerase II are present at the Bax CTSs.
Non–breast and breast cells (∼1 × 106) were prepared for ChIP and immunoprecipitated with the antibodies for repressive (me3H3K27
and me3H3K9) and active (me3H3K4 and H3K9Ac) chromatin and RNA Polymerase II (Pol II). DNA was extracted and qPCR was performed
using primers specific to Bax fragments 5 and 6. Results were calculated as the percentage of input chromatin precipitated at the region
of interest and presented as fold change relative to the control ChIP experiment with no antibody (designated as 1.0; see Materials and
Methods section for details). Experiments were performed in triplicate and the mean value is shown. Error bars indicate SDs. (C) RNA
Polymerase II is present at the TATA box of Bax gene. The ChIP experiments were conducted as described in B; primers overlapping
the TATA box Bax gene were used for qPCR.
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Figure 6. CTCF preferentially binds to the CTSs in the Bax promoter in breast cancer cells and tumors, whereas occupancy with other
factors is enriched in non–breast cells and normal tissues. Cells or fresh tissues were prepared for ChIP and immunoprecipitated with
the following antibodies: anti-CTCF, SP1, WT1, EGR1, and c-Myc [30]; DNA was extracted and qPCR was performed using primers spe-
cific to Bax fragment 5 or fragment 6 as described under Materials and Methods section. Results were calculated as the percentage of
input chromatin precipitated at the region of interest and presented as fold change relative to the control ChIP experiment with no antibody
(designated as 1.0). Experiments were performed in triplicate and the mean value is shown. Error bars indicate SDs. (A) Analysis of CTCF
binding to the Bax promoter in breast and non–breast cell lines. (B) Analysis of CTCF, SP1, WT1, EGR1, and c-Myc binding to the Bax
promoter in breast and non–breast cell lines. (C) Analysis of CTCF, SP1, WT1, EGR1, and c-Myc binding to the Bax promoter in normal
and tumor breast tissues (specimen 1094). The rabbit polyclonal anti-CTCF antibody (Abcam) and Protein A-BioVyon gravity free flow
columns (Porvair Technology) were used in these experiments [33].
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is very difficult to ascertain which CTCF threshold levels would be
necessary and sufficient to commit cells to apoptosis. Indeed, varia-
tions of CTCF levels were observed in apoptotic cells, which may be
explained by different sensitivity of cells due to different physiological
states (e.g., cell cycle). We also demonstrate that the previously de-
scribed apoptotic events in breast cancer cells with reduced CTCF
levels are mainly driven by overexpression of Bax. In these cells, simul-
taneously treated with CTCF siRNA and Bax siRNA, the levels of
the cleaved PARP-1 fragment of 89 kDa are decreased and more viable
cells are observed than in those transfected with the CTCF siRNA
only. However, it should be noted that these Bax-independent path-
ways may also be involved, as the apoptotic events are not completely
compensated by Bax knockdown (also see below).
The direct role of CTCF in the regulation of the Bax gene was sup-
ported by the identification of two CTSs within the Bax gene promoter
(“CTS-1” in fragment 5 and “CTS-2” in fragment 6). While sequences
within these fragments comply with the previously identified CTCF
“consensus”motif [42], methylation interference assays in combination
with mutational analysis will be necessary for precise identification of
the contact nucleotides. This information will also be useful for accu-
rate measurements of CTCF occupancy at each site by ChIP assays.
Interestingly, both sites are located downstream of the transcription start
site, which is characteristic for genes negatively regulated by CTCF
[34,45]. The presence of negative CTCF-dependent elements within
the Bax promoter was also confirmed in reporter assays: the reporter
construct was repressed by the exogenously supplied CTCF in all the
cell lines tested, breast and non-breast. The repressive function of
CTCF in both cell types is not surprising as the transfected DNA
lacks the appropriate chromatin environment, likely to be important
for CTCF-specific function in vivo in a particular cell context.
We also found that the Bax gene was active in all cell lines and tis-
sues tested. The DNA region containing the CTSs was also enriched
with the marks characteristic for open chromatin and unmethylated in
all specimens analyzed. Because only breast cancer cells were sensitive
to CTCF depletion, we proposed a model of epigenetic regulation of
Bax in different cell contexts, whereby different sets of transcription
factors, activators and repressors, occupy the regulatory elements of
the gene and control its function (Figure 8). We hypothesize that,
in breast cancer cells, elevated levels of CTCF [11] favor preferential
binding to the CTSs (Figure 8, A and B) by CTCF but not other
transcription factors. Of note, in further support of the specific func-
tion of CTCF in breast cells is that overexpression of CTCF in non–
breast cells does not lead to changes in Bax production or the increase
of CTCF association with the CTSs. In non–breast cells and in normal
breast tissues, less CTCF but more other factors bind to the Bax
promoter. The composition and abundance of such factors may be
different in these two contexts; this is indicated by differently posi-
tioned and sized circles (Figure 8, C and D). In contrast, in non–breast
cells where removal of relatively small amounts of bound CTCF does
not change the overall balance between negative and positive regula-
tors, apoptosis does not occur (Figure 8E). In breast cancer cells, more
CTCF is bound to Bax; following depletion, the negative influences of
Figure 7. Binding of CTCF and other factors to the CTSs in the Bax promoter is similar in K562 cells ectopically overexpressing CTCF and
in control K562 cells. (A) Western blot analysis of leukemia cells K562, K562EV, and K562-G1. Cellular extracts (20 μg of total protein)
were loaded onto SDS-PAGE, separated, blotted, and probed with the anti-Bax antibody. The same membrane was stripped and reprobed
subsequently with the anti-CTCF and α-tubulin antibodies (loading control). K562-G1 cells are cells overexpressing CTCF, K562 cells are
original K562 unmodified cells, and K562EV cells are cells stably transfected with the backbone empty plasmid pcDNA3 [26]. (B) Analysis
of CTCF, SP1, WT1, EGR1, and c-Myc binding to the Bax promoter in K562, K562EV, and K562-G1 cells.
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CTCF are counteracted leading to hyperactivation of Bax and apop-
tosis (Figure 8F ). However, it must be acknowledged that transcrip-
tional regulation of Bax may be more complex and involve other
DNA elements and factors. Therefore, the proposed model should
be further validated and refined, for example, by analyzing changes
in other factors’ binding following CTCF knockdown and using
primary rather than established cell lines.
In this study, we provide evidence that the Bax-dependent pathways
play a very important part in the regulation of Bax by CTCF in breast
cancer cells and also the insight into the molecular mechanisms of this
regulation. However, because of particular properties of CTCF (e.g.,
numerous binding sites and multiplicity of functions) [1–3], CTCF
involvement in the regulation of apoptosis in breast cancer cells is likely
to be more global and not limited to Bax. Indeed, this proposition was
supported by the microarray and proteomics analyses that revealed
differential expression of a number of apoptotic genes/proteins in breast
cancer cells depleted for CTCF [48]. This project is the focus of our
ongoing work, which will be described in a separate research article
(C.F. Méndez-Catalá et al., manuscript in preparation).
Of note and in agreement with data elsewhere [46], the levels of Bax
mRNA in normal breast tissues were significantly higher than in the
corresponding tumors. In this study, this observation was confirmed
for Bax protein. The presence of Bax at higher levels in normal tissues
highlights the importance of active apoptotic processes for normal tis-
sue functions. However, progressive loss of Bax and, as a consequence,
apoptotic functions constitute the hallmarks of cancer in many tissues
[49]. However, as illustrated by this investigation, the molecular
mechanisms of Bax deregulation may vary in different tissues.
An interesting aspect of our previous [11] and current studies is that
the regulatory effects of CTCF on Bax and possibly other apoptotic
genes are likely to be p53 independent in breast cancer cell lines.
Indeed, similar observations were made here using cell lines contain-
ing wild-type p53 (MCF-7) and mutant p53 (ZR75.1). This may be
highly relevant to the observations that apoptosis can still occur through
p53-independent apoptotic processes in human cancer cells that lack a
functional p53 tumor suppressor protein [22]. The existence of such
p53-independent apoptotic pathways opens up attractive perspectives
for the development of anti–breast cancer therapies, independently
of tumors’ p53 status, which may be based on selective reduction of
CTCF in breast cancer cells. Interestingly, our preliminary experi-
ments demonstrate that the simultaneous treatment of breast cancer
cells, in which CTCF is silenced, with chemotherapeutic agents of
different classes, Taxol (antimicrotubule) and Mitoxantrone (DNA
topoisomerase II inhibitor), increases the sensitivity of these cells to
Figure 8. Model of the regulation of Bax gene by CTCF in different cell contexts. Horizontal gray bars depict the Bax gene promoter, two
CTSs were represented by green boxes, and Bax mRNA is shown as a curved blue line; the thickness of the curves reflects mRNA levels.
Octagons depict CTCF (red) and other transcription factors are shown inside the yellow circle. Different configurations of these factors
in different cell contexts are indicated by repositioned circles. (A and B) Breast cancer cell lines and tissues, respectively: binding of CTCF
is higher than other transcription factors. (C and D) Non–breast cancer cells and normal breast tissues, respectively: binding of other
transcription factors is higher than CTCF. (E) Knockdown of CTCF in non–breast cell lines has no effect. (F) Knockdown of CTCF leads to
activation of Bax and apoptosis in breast cancer cells. (For more detailed explanations, see main text.)
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the drugs, even at lower concentration of the drugs (Figure W10).
This finding may be very useful in the design of new therapeutic
strategies. Our current and future investigations aim to explore these
avenues further.
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Supplemental Materials and Methods
Real-time RT-PCR: Conditions and Primers
Sequences of the primers used were as follows: TBP (TATA Bind-
ing Protein), (For) 5′-gcccgaaacgccgaatata-3′ and (Rev) 5′-cgtggctct-
cttatcctcatga-3′; glyceraldehyde-3-phosphate dehydrogenase (GAPDH ),
(For) 5′-accacagtccatgccatcac-3′ and (Rev) 5′-tccaccaccctgttgctgta-3′;
CTCF, (For) 5′-agatcatgatttccagccca-3′ and (Rev) 5′-tgtgacagttcatgtgcaa-
ga-3′ [1] and Bax, (For) 5′-ctggacagtaacatggagctg-3′ and (Rev) 5′-cactcg-
gaaaaagacctctcg-3′ [2]; cyclophilin B, (For) 5′-tggcacaggaggaaagagcatc-3′
and (Rev) 5′-aaagggcttctccacctcgatc-3′ [3]. Each PCR generated only
the expected specific amplicon, as shown by the melting temperature
profiles of final products (data not shown). The comparative C t method
was used to assess relative changes in mRNA levels [4]. Thermal cycling
conditions were given as follows: 95°C for 10 minutes, followed by
40 cycles of amplification, consisting of 94°C for 10 seconds, 60°C for
20 seconds, and 72°C for 20 seconds followed by data acquisition. For
cyclophilin B, the PCR conditions were given as follows: initial denatura-
tion for 10 minutes at 95°C; cycle (×40): 95°C for 15 seconds, 60°C for
30 seconds, 72°C for 20 seconds, final elongation at 72°C for 5 seconds,
followed by data acquisition.
ChIP: Conditions and Primers for Real-Time PCR
Thermal cycling conditions were given as follows: 95°C for 10 min-
utes followed by 35 or 40 cycles of amplification (95°C for 15 seconds
and 60°C for 20 seconds). Primers used for ChIP were given as
follows: Bax fragment 5, (For) 5′-ggcattagagctgcgattgg-3′ and (Rev)
5′-cgtgacgggaccaaacctccc-3′; Bax fragment 6, (For) 5′-gggagcgagg-
caggtgcggt-3′ and (Rev) 5′-cacgtgacccgggcgcgct-3′; TATA box of Bax
gene, (For) 5′-ttgctagatccaggtctctgca-3′ and (Rev) 5′-agcgcagaaggaat-
tagcaagt-3′.
DNase I Footprinting: Primers and Conditions
The DNase I footprinting analysis was performed according to a pre-
viously described protocol [5] with the in vitro translated, full-length
CTCF and two CTCF binding fragments 5 and 6 that were amplified
by PCR. The following primers were used for PCR amplification: for-
ward 5′-acttgctaattccttctgcgg 3′ and reverse 5′-cgtgaccgcacctgcctcgct
primers from the plasmid pBax5-pDrive (PCR fragment 5 cloned into
pDrive vector; Qiagen) and forward 5′-ggacagtcacgtgacgggacc 3′ and re-
verse 5′-gccgcctctcgccgggtccgcg 3′ primers from the plasmid pBax6-
pDrive (PCR fragment 6 cloned into pDrive vector). The amplification
protocol was given as follows: denaturation at 95°C for 5 minutes, fol-
lowed by 35 cycles at 95°C for 30 seconds, 64°C for 30 seconds, 72°C
for 1 minute, and final extension at 72°C for 10 minutes. The frag-
ments were labeled at their 5′ ends on either the top or the bottom
strand. Following gel purification, the fragments were incubated with
CTCF and then partially digested with DNase I.
Bisulfite Conversion of DNA
GenomicDNA (500 ng) was treated using the EZDNAMethylation-
Gold Kit (Zymo Research, Irvine, CA) as recommended by the manu-
facturer. The primers used for amplification of Bax promoter from the
treated DNA were as follows: (Forward) 5′-ggtgtttggataaatgaaggtat-3′
and (Reverse) 5′-aaaatttctacccctcaatactta-3′. PCR fragments were ligated
into the TOPO TA cloning vector (Invitrogen, Carlsbad, CA). Fol-
lowing transformation, plasmids from individual colonies were iso-
lated and the Bax promoter was sequenced (GeneService, Cambridge,
United Kingdom). Single clone sequences were analyzed with the BiQ
Analyzer software (Max-Planck-Institut für Informatik, Saarbrücken,
Germany) [6].
Drug Treatments
Taxol (paclitaxel) and Mitoxantrone (both obtained from Sigma-
Aldrich) were diluted in DMSO (Taxol) or water (Mitoxantrone)
and stored according to the manufacturer’s instructions. MCF-7 and
ZR75.1 breast cancer cells were transfected with 50 pM CTCF siRNA,
50 pM non-target siRNA, or transfection reagent only (“Mock”).
Twenty-four hours post-transfection, cells were treated with trypsin,
counted, replated onto 96-well plates (5 × 104 per well), and incubated
overnight. After a total of 48 hours post-transfection, the medium was
changed to the phenol-free RPMI containing Taxol at different concen-
trations (indicated in the figure) and left for further 24 hours. Triplicate
wells were used for each concentration. Cell survival was measured using
MTT assay (Sigma-Aldrich) as described in the manufacturer’s manual.
Briefly, 20 μl of 5 mg/ml MTT was added to the wells and cells were
incubated at 37°C for 3.5 hours. The medium was then removed,
and 150 μl of the MTT solution was added to the cells for further
incubation for 15 minutes at room temperature with shaking. The
OD590 and OD620 were read using Versamax plate reader. Control
cells were treated with DMSO (0.1%) or water alone. Cell survival
was calculated as a percent of control (DMSO-treated in experiments
with Taxol or water-treated in experiments with Mitoxantrone) cells as
described previously [7].
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Figure W1. Transient knockdown of CTCF by CTCF siRNA induces apoptotic cell death in breast cancer cells, MCF-7. (A) Levels of CTCF
are reduced in breast cancer cells, MCF-7, treated with the Hs_CTCF_4 siRNA as shown by Western blot analysis. Cells (2.5 × 105) were
transfected with 50 pM target Hs_CTCF_4 siRNA (CTCF siRNA, “CTCF”), non-target siRNA (“NT”), or transfection reagent only (“Mock”).
Forty-eight hours post-transfection, cells were collected, cellular extracts were prepared, and equal amounts (40 μg) of total protein were
loaded onto SDS-PAGE. Samples were electrophoretically separated, blotted, and probed with the mouse monoclonal anti-CTCF antibody
(BD Biosciences). The membrane was reprobed with the anti–α-tubulin antibody, which served as an internal control for protein loading.
(B) Apoptotic cell death is induced by CTCF knockdownwith the CTCF siRNA in breast cancer cells, MCF-7. Cells (2.5× 105) were transiently
transfected with 50 pM CTCF siRNA, non-target siRNA (“NT”), or transfection reagent only (“Mock”), and apoptotic cell death was assessed
by TUNEL assay. The percentage of TUNEL-positive cells was calculated 48 hours after transfection. The results represent the mean values
with the SDs (error bars) of three independent experiments. (C) Images were additionally analyzed using the ImageJ software [8]. The values
were measured for CTCF and TUNEL staining in 100 cells; and the mean values for fluorescence were normalized by subtracting the
background values. The results are presented as a scatter plot.
Figure W2. Transient knockdown of CTCF by SMARTpool CTCF siRNA induces apoptotic cell death in breast cancer cells. (A) Levels of
CTCF are reduced in the breast cancer cells following CTCF knockdown, as shown by Western blot analysis. Breast cancer MCF-7 (2.5 ×
105) and ZR75.1 (2.5 × 105) cells were transfected with 50 pM SMARTpool siRNA (CTCF siRNA, “CTCF”), 50 pM non-target siRNA (“NT”), or
transfection reagent only (“Mock”). Forty-eight hours post-transfection, cells were collected, cellular extracts were prepared, and equal
amounts (40 μg) of total protein were loaded onto SDS-PAGE. Samples were electrophoretically separated, blotted, and probed with the
mouse monoclonal anti-CTCF antibody (BD Biosciences). The membrane was reprobed with the anti–α-tubulin antibody, which served
as an internal control for protein loading. (B) Lower CTCF levels are associated with apoptotic death in breast cancer cells, ZR75.1. Cells
(2.5 × 105) were transfected with 50 pM SMARTpool CTCF siRNA and analyzed by immunofluorescence staining with the anti-CTCF anti-
body (FITC, green fluorescence). Apoptotic cell death was assessed by TUNEL staining (TMR, red fluorescence). Nuclei were visualized
by DAPI. Merge, overlay of the CTCF and TUNEL staining. TUNEL-positive (apoptotic) cells with low CTCF levels are indicated by white
arrows. The TUNEL-negative cells with high levels of CTCF are indicated by yellow arrows.
Figure W3. Transfection with the cyclophilin B siRNA leads to the
reduction of the cyclophilin BmRNA levels in non–breast (HeLa and
293T) and breast cancer (MCF-7 and ZR75.1) cell lines. Cells were
transfected with 50 pM cyclophilin B siRNA and collected 12, 24,
and 48 hours post-transfection. The reagent-only (“Mock”) reaction
was used as control. The total RNA was extracted and analyzed by
RT-qPCR. The expression of cyclophilin B was normalized to TBP
mRNA expression, and the comparative C t method (ΔΔC t) was
used to calculate relative cyclophilin BmRNA levels. Columns repre-
sent fold change of cyclophilin B/TBP relative to mock-transfected
cells (designated as 1.0). For each sample, measurements were
performed at least in triplicates; error bars represent SDs.
Figure W4. Levels of Bax mRNA and Bax protein increase in breast
cancer cells following CTCF knockdown by the CTCF–SMARTpool
siRNA. (A) Analysis of Bax mRNA. Breast cancer ZR75.1 (2.5 × 105)
and MCF-7 (2.5 × 105) cells were transfected with 50 pM CTCF–
SMARTpool siRNA, non-target siRNA (control), or transfection re-
agent only (“Mock”) and harvested 48 hours post-transfection. Total
RNA was prepared and analyzed by RT-qPCR. The expression levels
of CTCF (upper panel) and Bax mRNA (lower panel) were calculated
using the comparative C t method (ΔΔC t) and normalized to GAPDH
mRNA expression, representing fold change of CTCF/GAPDHmRNA
or Bax/GAPDH levels relative to mock-transfected cells (designated
as 1.0). For each sample, measurements were done at least in tripli-
cates. Columns, mean mRNA/GAPDH relative level values. Bars,
SDs. The difference in CTCF mRNA and Bax mRNA levels between
cells treated with CTCF siRNA and control (non-target, NT) siRNA
was statistically significant (P≤ 0.01). (B) Analysis of Bax protein lev-
els. Following transfection as described above, cells were lysed,
proteins separated by SDS-PAGE, blotted, and analyzed by Western
blot analysis using CTCF, Bax, and α-tubulin (loading control) anti-
bodies. Abbreviations: CTCFsi, CTCF siRNA; NT, non-target siRNA;
M, transfection reagent only (“Mock”); two controls in the right lanes
are extracts from untreated cells.
Figure W5. The full-length CTCF binds to fragments 5 and 6 within
the promoter-proximal region of human Bax gene in the EMSA.
EMSA analysis of CTCF binding to two overlapping fragments,
5 and 6, of the human Bax promoter. The DNA fragments were
end-labeled with 32P, and EMSA analyses were performed as de-
scribed under Materials and Methods section. The in vitro translated
11-Zn-finger domain of CTCF (CTCF-ZnF), full-lengthCTCF (CTCF-Full),
and luciferase (control, Luc) were used to assess specific and non-
specific binding to the DNA. Free, free probe. Specific ZF-CTCF-
DNA and CTCF-DNA complexes are indicated by red arrows.
Figure W6. Footprinting analysis of CTCF binding to fragments 5 and 6 of the Bax gene promoter. (A) The 5′-32P end-labeled fragments
containing promoter regions between +24 and +226 (fragment 5) and +174 and +358 (fragment 6) downstream of the transcription start
site were used as probes in the binding reaction with in vitro translated full-length CTCF. ACGT, the Maxam-Gilbert sequencing reactions;
F, free probe; B, bound probe (reaction with CTCF). The strongly and weakly protected regions are indicated by black and gray lines,
respectively. HS, hypersensitive sites; FP, footprint. Coordinates of the binding sites: chr19: 54,149,742 to 54,149,922. Coordinates are
from the UCSC genome browser. (B) The sequences of the two CTCF bound fragments 5 and 6 within Bax promoter region. The lines
on the top and bottom of double-stranded DNA sequences summarize the CTCF footprint on the top and bottom strands, respectively.
(C) Analysis of the ChIP-seq data for CTCF binding in MCF-7 cells in the UCSC genome browser [http://genome.ucsc.edu/ (NCBI36/
hg18)]. Enrichment in CTCF is detected in the regions where CTSs in theBax promoter weremapped (boxed in yellow). Coordinatesmapped
by ChIP-Seq: chr19: 54,149,575 to 54,149,958. (D) The maps depicted in C are shown at higher resolution. The positions of the transcrip-
tion start site and translation start are indicated by the green and red arrows, respectively; the positions of the sites are given in brackets.
Locations of fragments 5 and 6 are shown on the expanded maps below.
Figure W6. (continued).
Figure W7. Open chromatin configuration is detected in the regions containing CTSs in the Bax promoter (boxed in yellow, coordinates
are shown on top of the diagram) in a variety of breast and non–breast cells: analysis of the ChIP-seq data in the UCSC genome browser
[http://genome.ucsc.edu/ (NCBI36/hg18)]. Typical examples are shown; they include HUVEC (human umbilical vein endothelial cell),
HMEC (human mammary epithelial cells), GM12878 (lymphoblastoid), H1-hESC (human embryonic stem cells), HepG2 (liver carcinoma),
and K562 (leukemia). Green arrows, histone marks associated with open chromatin; red arrows, histone marks associated with closed
chromatin; blue arrows, dual histone marks (open and close chromatin).
Figure W8. The Bax promoter is unmethylated in breast and non–breast cells and in normal and tumor breast tissues. As described
under the Supplemental Materials and Methods section, genomic DNA (500 ng) from non–breast (HeLa and 293T) and breast (Cama1,
MCF-7, and ZR.75.1) cell lines, two tumors (89T and 68T), and paired peripheral to tumors (89N and 68N) was purified, treated with
bisulfate, amplified by PCR, and cloned. The plasmids from individual colonies were isolated and the Bax promoter was sequenced.
DNA methylation status of CpG islands within fragments 5 and 6 is indicated as lollipop figures. Filled lollipops refer to methylated sites;
open lollipops refer to unmethylated sites.
Figure W9. The CTSs are enriched with CTCF in breast cancer cells compared with normal breast and non–breast cancer cells. Analysis
of CTCF binding to the Bax promoter in normal and tumor breast tissues (specimens 250 and 252, upper and lower panels, respectively)
using ChIP assays. Cells were fixed with 1% formaldehyde to cross-link protein-DNA interactions and sonicated, and DNA-protein com-
plexes were immunoprecipitated with the rabbit polyclonal anti-CTCF antibody (Abcam) [9]. The DNA was extracted and real-time PCR
was performed using primers specific to Bax fragment 5 or fragment 6 as described under Materials and Methods section. Results were
calculated as the percentage of input chromatin precipitated at the region of interest and presented as fold change relative to the control
ChIP experiment with no antibody (designated as 1.0). Experiments were performed in triplicate, and the mean value is shown. Error
bars indicate SDs.
Figure W10. Cytotoxic effect of Taxol (paclitaxel) and Mitoxantrone in MCF-7 and ZR75.1 breast cancer cells. MCF-7 and ZR75.1 cells
were transfected with 50 pM CTCF siRNA, 50 pM non-target siRNA, or transfection reagent only (“Mock”). Cells were treated with trypsin
(24 hours post-transfection), counted, replated onto 96-well plates (5 × 104 per well), and incubated overnight. After a total of 48 hours
post-transfection, the medium was changed to the phenol-free RPMI containing the drugs at the indicated concentrations and left for fur-
ther 24 hours. Cell survival wasmeasured usingMTT assay (see SupplementalMaterials andMethods section for details). Control cells were
treated with DMSO (0.1%) or water alone. Cell survival was calculated as a percent of control (DMSO-treated in experiments with Taxol
or water-treated in experiments with Mitoxantrone) cells as described previously [7]. The results represent the mean values with the SDs
(error bars) of three independent experiments. The difference in the survival of cells treated with Taxol or Mitoxantrone at all concentrations
was significantly less for cells transfected with the CTCF siRNA compared with other conditions (P ≤ 0.01). Abbreviations: CTCFsi, CTCF
siRNA; NT, non-target-siRNA; Mock, transfection reagent only; C, control (cells only).
